Navigation Links
Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant
Date:1/30/2010

The Anson Group is pleased to announce that Dr. Michael Langley is joining the company as a regulatory consultant after retiring from Eli Lilly & Co. Dr. Langley served many roles during his career with Lilly in both animal science and human pharmaceutical products, including director of regulatory affairs and clinical research. Dr. Langley led a number of successful regulatory engagements including both European and US regulatory submissions.

Indianapolis, IN (Vocus) January 30, 2010 -- The Anson Group announces today the addition of Dr. Michael Langley to its regulatory consulting practice. Dr. Langley is joining Anson Group after his recent retirement from Eli Lilly and Co. He has worked in the pharmaceutical industry since 1983, and has had a range of responsibilities and a broad variety of pharmaceutical products.

Early in his career, Dr. Langley worked for Elanco Animal Health, a Division of Eli Lilly, in a number of roles with increasing responsibilities including market research manager, project manager of animal health research, Director of European Regulatory and Clinical Affairs, and finally director of clinical research.

In 2002, Dr. Langley transitioned from animal health products to human pharmaceuticals at Eli Lilly. His experience includes establishing research priorities and timelines, successfully leading teams through US and EU marketing applications.

As the Director for Regulatory Affairs for Eli Lilly, Dr. Langley led project teams in label negotiations with the FDA, and several sNDA and sBLAapplications which resulted in approvals. Additionally, he has successfully guided several IND submissions, and also worked with FDA officials to remove a clinical hold placed on one molecule.    

“As we further expand the depth and breadth of our regulatory team, the addition of Dr. Langley’s oncology and CVM experience significantly contributes to our goal of providing the most experienced personnel needed to meet the exacting demands of every client project.” states Colleen Hittle, RAC, Managing Partner.


About Anson Group
Headquartered in Carmel Indiana, Anson Group is a minority-owned independent consulting organization with over 14 years experience as a leading provider of services and strategies for FDA product approval and compliance for devices, drugs, biologics, and combination products. Anson Group’s team of experienced industry experts tailors both enterprise strategies and clearly-defined action plans that help its clients address crucial issues throughout the product life cycle. Anson works with clients in the United States, Europe, and Asia, from global pharmaceutical manufacturers to small pre-IPO or VC biotechnology and medical device start-ups.

###

Read the full story at http://www.prweb.com/releases/regulatory/01/prweb3540554.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Michael Troullis Appointed Chief Financial Officer of Quintiles Transnational Corp.
2. Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer
3. Genstar Names Michael Hurt to Its Strategic Advisory Board
4. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
5. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. The Michael J. Fox Foundation Awards $2 Million to Shed Light on Role of LRRK2 and Alpha-Synuclein Genes in Parkinsons Disease
8. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
9. Michael J. Simms Joins Alexza Pharmaceuticals as Senior Vice President, Operations and Manufacturing
10. Dr Michael Rosenblatt Appointed Non-Executive Director at Shire
11. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant
(Date:6/20/2017)... ... ... Do More with OHAUS , With the launch of the new laboratory ... industry, to extending its expertise across the entire laboratory to a range of life ... allowing for its customers to 'Do More' in the lab. , Efficiency and ...
(Date:6/19/2017)... ... June 19, 2017 , ... A colony of healthy ... cells and tissues by delivering pollen and nectar containing nutrients necessary for growth and ... stay healthy. , Many recent indicators point to a decline in honey bee health. ...
(Date:6/15/2017)... ... June 15, 2017 , ... ... a Series B round of financing in the amount of $6 million. An ... investors participated in the round. , The Series B funding will enable Cybrexa ...
(Date:6/14/2017)... , ... June 14, 2017 , ... ... 8th to discuss the initiative steered by the executive search firm, “Building Value ... of the Board of Directors of Foundation Medicine, led an open discussion with ...
Breaking Biology Technology:
(Date:4/13/2017)... Calif. , April 13, 2017 UBM,s ... York will feature emerging and evolving technology ... Both Innovation Summits will run alongside the expo portion ... speaker sessions, panels and demonstrations focused on trending topics ... largest advanced design and manufacturing event will take place ...
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
Breaking Biology News(10 mins):